中国危重病急救医学
中國危重病急救醫學
중국위중병급구의학
CHINESE CRITICAL CARE MEDICINE
2001年
4期
205-207
,共3页
黄建荣%李兰娟%陈月美%陈江华%朱琮%干梦九
黃建榮%李蘭娟%陳月美%陳江華%硃琮%榦夢九
황건영%리란연%진월미%진강화%주종%간몽구
重型病毒性肝炎,慢性%人工肝支持系统%临床评价
重型病毒性肝炎,慢性%人工肝支持繫統%臨床評價
중형병독성간염,만성%인공간지지계통%림상평개
目的:探讨人工肝支持系统(ALSS)治疗慢性重型病毒性肝炎的临床价值。方法:应用ALSS治疗55例(162次)慢性重型肝炎患者,并同时选择常规治疗56例患者作为对照组;每次ALSS治疗前后检测生化和免疫指标。结果:每次ALSS治疗后患者肝功能显著改善,球蛋白降至正常参考值范围;血内毒素含量下降;但肿瘤坏死因子、白介素2、白介素2受体、电解质等每次治疗前后无明显改变;ALSS治疗的并发症主要为皮疹、低血压等,但大多数患者能耐受;临床治愈好转率61.8%,明显高于对照组17.9%(P<0.01)。结论:ALSS是辅助治疗重型病毒性肝炎的有效方法。
目的:探討人工肝支持繫統(ALSS)治療慢性重型病毒性肝炎的臨床價值。方法:應用ALSS治療55例(162次)慢性重型肝炎患者,併同時選擇常規治療56例患者作為對照組;每次ALSS治療前後檢測生化和免疫指標。結果:每次ALSS治療後患者肝功能顯著改善,毬蛋白降至正常參攷值範圍;血內毒素含量下降;但腫瘤壞死因子、白介素2、白介素2受體、電解質等每次治療前後無明顯改變;ALSS治療的併髮癥主要為皮疹、低血壓等,但大多數患者能耐受;臨床治愈好轉率61.8%,明顯高于對照組17.9%(P<0.01)。結論:ALSS是輔助治療重型病毒性肝炎的有效方法。
목적:탐토인공간지지계통(ALSS)치료만성중형병독성간염적림상개치。방법:응용ALSS치료55례(162차)만성중형간염환자,병동시선택상규치료56례환자작위대조조;매차ALSS치료전후검측생화화면역지표。결과:매차ALSS치료후환자간공능현저개선,구단백강지정상삼고치범위;혈내독소함량하강;단종류배사인자、백개소2、백개소2수체、전해질등매차치료전후무명현개변;ALSS치료적병발증주요위피진、저혈압등,단대다수환자능내수;림상치유호전솔61.8%,명현고우대조조17.9%(P<0.01)。결론:ALSS시보조치료중형병독성간염적유효방법。
Objective:To evaluate clinically the treatment with artificialliver support system (ALSS) in chronic fulminant viral hepatitis.Methods:Fiftyfive cases (162 episodes) were treated with ALSS,56 cases with convontional treatment as controls.Immunological and biochemical tests were performed before and after treatment with ALSS.Results:It showed that liver function parameters were markedly improved after treatment with ALSS,e.g.,serum globulin returned to normal,serum endotoxin decreased.There were no changes in levels of tumor necrosis factor(TNF),interleukin2(IL2) as well as interleukin2 receptor(IL2R),and blood electrolyte etc.after ALSS treatment.Complications of ALSS included rash,hypotention etc.,but most patients could tolerated well.Clinical curative rate in ALSS group was much higher than in the controls (61.8% vs.17.9%,P<0.01).Conclusions:Our results showed that ALSS treatment in chronic fulminant viral hepatitis could alleviate the organ damage and improve the clinical curetive rate.